A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

India’s Ministry of Health and Family Welfare has issued an advisory stating that stem cell therapy should be used as standard care only for diseases or indications approved by the Ministry.

The advisory reiterates the existing regulatory framework governing stem cell research and therapy.

What Does The Advisory Say?

The advisory directs that stem cell therapy for Autism Spectrum Disorder (ASD) be restricted to approved clinical trials.

This aligns with the National Guidelines for Stem Cell Research, 2017, issued by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), along with other applicable government instructions.

The advisory also says unproven stem cell interventions, including those for ASD, should not be offered as “routine, standard or commercial clinical services.”

“All States and Union Territories must adopt the Clinical Establishments (Registration and Regulation) Act, 2010, regarding regulation of stem cell therapy,” the Ministry said.

The directions apply to government and private clinical establishments involved in stem cell research, treatment, promotion or administration.

The Supreme Court had earlier ruled against the use of stem cell therapy for autism outside approved clinical trials. The National Medical Commission (NMC) has also warned doctors and hospitals against offering it as routine treatment for ASD.

Also read: Autism Care Begins Early: Why the First 1,000 Days Matter Most, Says AIIMS Expert

Action Against Violations

The Ministry has asked States and Union Territories to ensure that hospitals, clinics and other establishments involved in stem cell research or treatment comply with the regulatory framework.

The Supreme Court, in its January 30, 2026 judgment, said violations can lead to professional misconduct proceedings, as well as action under the Clinical Establishments Act, including cancellation of registration and penalties.

NMC: Stem Cell Therapy Only For Approved Uses

Read More: Could Tylenol Taken During Pregnancy Affect Girl Child’s Future Reproductive Health? Study Raises Concern

In its September 5, 2026 advisory, the National Medical Commission (NMC) said stem cell therapy can be offered as standard clinical care only for approved indications.

Unauthorized administration, prescription, promotion or advertising of stem cell therapy beyond approved indications may amount to professional misconduct, it said.

State Medical Councils have been asked to examine alleged violations and take disciplinary action where professional misconduct by a registered medical practitioner is established after due process.

Which Diseases Can Be Treated With Stem Cells?

Earlier this year, ICMR Director-General Dr Rajiv Bahl told the NMC that stem cell treatment could be used in regular medical practice only for 32 government-approved diseases.

These include:

• Acute myeloid leukemia
• Thalassemia
• Multiple myeloma
• Aplastic anemia
• Myelofibrosis
• Germ cell tumors

The ICMR DG asked doctors not to offer stem cell therapy for diseases outside the approved list. Current international guidelines also do not recommend stem cell therapy as a treatment for ASD.

What Did The Supreme Court Say?

In January, a Supreme Court bench comprising Justice JB Pardiwala and Justice R Mahadevan said stem cell therapy lacks “scientific support” and has not been recognized as a sound medical practice backed by empirical evidence.

The Bench ruled that “every use of stem cells in patients outside an approved clinical trial is unethical and shall be considered as malpractice.”

The Court said stem cell therapy can still be studied through monitored clinical research trials, and patients can participate in approved and regulated trials.

What Is Stem Cell Therapy?

Stem cell therapy, also called regenerative medicine, uses stem cells to repair or replace damaged tissues.

While stem cell therapy is used for certain blood cancers and blood disorders, there is no established scientific evidence supporting its use as a treatment for autism.

Stem cell therapy remains vastly unregulated in India, and some private labs have been making money by promising treatment for autism, according to experts.

Stanford University scientists have grown lab-made human brain tissue inside mice, successfully creating a new kind of animal model whose constitution is the closest to those of humans. This could help researchers study brain development and neurological diseases in living organisms with a lot more accuracy.

The study, published in Nature recently, discusses mice whose cerebral cortex was largely replaced by human brain tissue grown from stem cells.

The human tissue expanded to occupy more than 90% of the space available for the mouse cortex and formed connections with the animals' nervous systems successfully.

The researchers call them xenocortical mice. The breakthrough could provide scientists with a way to study human neurons in a living brain, something that cannot be done directly in people and is difficult to reproduce using conventional laboratory models.

How Did Scientists Create A Part-Human Brain In Mice?

The researchers first genetically engineered mice so that most of the cells destined to form their cerebral cortex and hippocampus would not develop. This created space for human brain tissue.

Then they transplanted human cortical organoids, three-dimensional structures made from human stem cells, into the brains of newborn mice.

The organoids were able to grow rapidly inside the animals. In successful transplants, the human tissue expanded nearly five-fold over a period of three months and eventually occupied more than 90% of the available cortical space.

The human cells also developed different types of neurons and formed connections with the mouse brain and, in some cases, extended nerve fibres into the spinal cord. It is important to note that these are not mice with an entirely human brain.

The animals still have a mouse nervous system, including their sensory organs and deeper brain structures. What has been humanised is the cortex, the outer part of the brain involved in functions including perception, learning, and complex information processing.

Also read: Cefepime: Antibiotic Used For Pneumonia, UTI Linked To Higher Death Risk In Adults

Why This Could Be A Milestone For Brain Disease Research?

One of the biggest problems in neuroscience is that findings in mice do not always translate to humans.

Human brain organoids grown in laboratory dishes have helped researchers study development and disease, but they lack many features of a living brain. They do not receive normal sensory information or interact with muscles and other organs. Putting human neural tissue inside a living animal provides that missing environment.

The Stanford researchers tested the model by exposing the mice to a temporary lack of oxygen. The human cortical cells showed significant damage, and the animals developed movement and coordination problems. This provided a way to observe how developing human neural tissue responds to an injury inside a living organism.

The researchers say the approach could eventually help investigate conditions including cerebral palsy, epilepsy, autism, schizophrenia and other neurodevelopmental or neurological disorders, while also providing a platform for testing potential treatments.

Also read: India’s Hidden Stillbirth Burden: Lancet Study Finds 2.2 Lakh Pregnancy Losses Missed By Current Reporting Method

Ethical Questions

The experiment also raises difficult ethical questions. As scientists become increasingly capable of integrating human neural tissue into animals, researchers must consider whether increasingly sophisticated brain models could acquire unexpected characteristics or alter animal welfare.

The Stanford team sought outside ethical review of the work. Experts have emphasised that there is currently no evidence that these mice possess human-like consciousness, but they also argue that ethical oversight will become important as these models become more complex.

The death of a 16-year-old San Francisco boy has sparked concerns about the arrival of cychlorphine, a synthetic opioid that experts describe as 10 times more potent than fentanyl.

Dante Paul Lacourte died at his home on April 7 after taking drugs that contained cychlorphine. His death was the first confirmed cychlorphine-related overdose reported in San Francisco. The drug had already been linked to dozens of deaths elsewhere in the US.

The case has led to four arrests till now. San Francisco police said they seized more than 20,000 counterfeit pills, along with firearms, during searches connected to the investigation into the teenager's death.

What Is Cychlorphine?

Cychlorphine is a synthetic opioid that has crept up in the illicit drug supply in the last few years. It was first identified in the US in 2024 and belongs to a growing group of highly potent synthetic opioids.

The White House's Office of National Drug Control Policy warned in April that cychlorphine could be “up to ten times more potent than fentanyl” and linked it to 55 deaths across the US between 2025 and 2026. Tennessee has recorded the largest number of confirmed deaths so far.

Fentanyl is already notorious for being an extremely powerful opioid. Cychlorphine adds another layer of risk to an illicit drug supply that is already difficult to predict.

Also read: US FDA To Hold Psychedelic Drug Hearing Amid Trump Push: What It Means For Depression, PTSD

Users May Not Realise It Is There

Cychlorphine can be mixed into other drugs or pressed into counterfeit prescription pills, meaning someone may believe they are taking a familiar medication when the tablet actually contains a much more powerful opioid.

This was one of the concerns highlighted in the San Francisco case. Police said counterfeit pills had been seized from earlier, unrelated investigations and subsequently tested positive for cychlorphine, suggesting the drug was already circulating through multiple sources.

Another problem with cychlorphine is detection. Fentanyl test strips do not detect cychlorphine, so a negative fentanyl test does not mean a drug is free from cychlorphine.

Also read: RFK Jr-Backed ‘Wolverine’ Peptide Use Surges: Why Are People Taking An Unapproved Drug For Injury Recovery?

It Can Cause A Fatal Overdose

Like other powerful opioids, cychlorphine can suppress the central nervous system and slow or stop breathing.

Its high potency means very small amounts can potentially produce profound opioid effects.

Experts say the drug also increases the risk that a person could move rapidly from intoxication to life-threatening respiratory depression.

Naloxone, commonly known as Narcan, can reverse opioid overdoses, but the response to these extremely potent synthetic opioids can be complicated.

The New York Times reported that multiple doses of Narcan may be needed to reverse cychlorphine's effects, while people responding to an overdose may have only one or two doses available.

Also read: US FDA Launches Expedited IND Pilot To Speed Up Drug Trials

Officials Are Worried About Its Spread

San Francisco health officials say the emergence of cychlorphine shows how quickly the illicit drug supply can change.

Daniel Tsai, director of the San Francisco Department of Public Health, said, “What we see now with cyclorphine, a new category of synthetic opioids potentially 10 times more potent than fentanyl, of course, it’s a great cause for concern.”

He also stressed that the safest way to avoid the risk is not to take counterfeit pills or illicit drugs. San Francisco is now working on wastewater surveillance that could help detect cychlorphine and other novel drugs before they are identified through an overdose death.